Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase EARLY_PHASE1 1

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 4OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Histiocytic Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × ulixertinib × Clear all
NCT06411821 2026-05-28

Ulixertinib in People With Histiocytic Neoplasms

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
38 enrolled

Histiocytic Neoplasms

NCT03417739 2026-02-25

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Dana-Farber Cancer Institute

Phase 2 Terminated
13 enrolled 9 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡